LUMAXIND Q1 FY27 Guidance vs Delivery (LUMAXIND Management Mirror)

Q1 Jun'26 EBITDA Margin Reported at 9.0%; FY27 Guidance Reaffirmed at 10.5%-11.0% Contingent on Price Recoveries

In the Dec'25 Qtr concall, management guided for full-year FY26 margins in the double-digit range and targeted an EBITDA margin of close to 12% to 13% over the next two years. In the Mar'26 Qtr concall, FY27 EBITDA margin guidance was initiated between 10.5% and 11.0%, with a 3 to 4-year mid-term milestone of close to 13.0%. In the latest Jun'26 Qtr concall, management reaffirmed the FY27 EBITDA margin guidance of 10.5% to 11.0%, anticipating Q2 margins to exceed 10.0% as Q1 price recoveries flow through, and revised the 3 to 4-year target to upwards of 13.0%. For the Q1 Jun'26 quarter, management commentary cited an EBITDA margin of 9.2%, noting a 120 to 130 basis points impact from commodity price increases and delayed price amendment recoveries. The Quarterly Financial Results for the Jun'26 Qtr reported an actual EBITDA margin of 9.0%.